Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet
Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers.
November 16, 2026